Arriva Pharmaceuticals, Inc. has signed an agreement to develop and commercialise the synthetic matrix metalloprotease inhibitor (MMPI) Ilomastat for the treatment of inflammatory respiratory diseases.
“This is a further demonstration of our strategy, which aims to build a product pipeline in protease inhibitors and respiratory diseases,” said Martin Preuveneers, Ph.D., Chairman and CEO of Arriva.
“Our growing experience in the delivery of therapeutic molecules to the lung for the treatment of hereditary emphysema can now be applied to potential therapies for smoking-related emphysema and other chronic obstructive pulmonary disease states.”
The matrix metalloproteases are a group of enzymes known to be involved in the progression of a number of disease states, including metastatic cancer, cardiovascular disease and inflammatory disorders.
Recent evidence has also shown their involvement in the development of emphysema associated with cigarette smoking, as well as other pulmonary diseases, such as asthma and cystic fibrosis.
Ilomastat, also known as Galardin, is a broad spectrum, small molecule MMPI with potent biochemical activity against all of the damaging metalloproteases involved in the progression of lung disease, and demonstrated safety in humans.
“This important addition to our pipeline is made more significant following the recent finding that lung deterioration in smoking-related emphysema and other forms of COPD can potentially be inhibited by MMPIs,” commented Philip J. Barr, Ph.D., Arriva’s President and Chief Operating Officer.
Arriva is a biopharmaceutical company focused on the development of protease inhibitors for therapeutic applications.
Its lead therapeutics are for the treatments of hereditary emphysema and asthma using the protein protease inhibitor alpha 1-antitrypsin (AAT), the prototypic member of the serine protease inhibitor superfamily known as serpins.